BATON ROUGE, La. – Komen Louisiana will hold its inaugural Metastatic Breast Cancer (MBC) Conference on Saturday, June 8, 2019, at Pennington Biomedical Research Center Conference Center in Baton Rouge. The event is from 8 a.m. to 5 p.m. and is free and open to those living with metastatic breast cancer and their family and friend caregivers.
The daylong event provides discussions on emerging research, treatment options, and quality of life issues with nationally respected experts. Breakout sessions will focus on breast cancer by sub-type and metastatic location. Additional highlighted information will include details on clinical trials, nutrition, legal matters, financial toxicity, Komen public policy initiatives surrounding MBC, and other matters of interest.
Komen Scholar, Ian Krop, MD, Ph.D., is a clinical translational medical oncologist whose primary research focuses on understanding and overcoming mechanisms of resistance to HER2-directed therapies. Dr. Krop will share about his role and the development of new therapy for HER2-positive breast cancers, including metastatic breast cancer. Dr. Krop is currently leading several clinical trials exploring combinations of novel targeted therapies designed to overcome resistance to HER2-directed agents.
The event will be live-streamed on the Komen Louisiana Facebook page to ensure the accessibility of information for those who are unable to attend. Registration is open to Louisiana residents and others living with MBC at komenlouisiana.org/mbc.
For more information about the Komen Louisiana Metastatic Breast Conference, contact the affiliate at info@komenlouisiana.org or by calling 225-615-8740.
